echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The same vaccine may be available to all people around the world

    The same vaccine may be available to all people around the world

    • Last Update: 2020-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    U.S. researchers analyzed the genetic sequences of more than 27,000 people infected with the new coronavirus and concluded that the virus had limited variation points, suggesting that people around the world may be using the same new coronavirus, Physicist.com reported recently. The latest study was published recently in the
    National Journal of National Sciences.
    To show how the new coronavirus has changed since the outbreak began, a team led by Morgan Rowland of the Walter Reed Army Institute (WRAIR) compared the virus genome sequences from samples from 84 countries and combed through the variations. The analysis showed limited diversity across the neo-coronavirus genome: only 11 bits showed polymorphism greater than 5%. Until now, the evolution of the new coronavirus genome has been primarily a random process, not an adaptive choice.
    "As other studies have noted, we have noticed a rapid increase in the frequency of D614G mutations in the new coronavirus pyrethroid protein since the outbreak, but we cannot link this mutation to specific adaptability," Roland said. When the virus replicates and spreads in a population, we see mutations that can be fixed quickly and randomly. Roland
    that linking genotypes to esotypes is complex and more research is needed to fully understand the functional consequences of D614G mutations in the new coronavirus. In addition, given the limited genetic variation of the new coronavirus, promising candidate vaccines may have the same effect on all new coronavirus strains currently in transmission. "Efforts
    develop vaccines such as influenza, influenza and dengue face the challenge of diversity of these viruses, but analysis of samples from around the world shows that the diversity of new coronavirus is lower than that of these viruses. Therefore, we can be cautiously optimistic that virus diversity will not be an obstacle to the development of a broad range of protective vaccines against new coronavirus infections. It
    that WRAIR is also currently developing a vaccine, its candidate vaccine based on the prickly ferrin nanoparticle platform, is expected to be conducted in humans by 2021. The vaccine is paired with WRAIR's patented adjunction, the Army Lipid Formula, to further enhance the immune response.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.